24 | Press release
PR displayed 2735 times
The French speciality pharmaceutical company, Juvisé Pharmaceuticals acquires two oncology products from AstraZeneca in over 40 countries
Published on 12/20/2019, 10:51 AM
The French speciality pharmaceutical company, Juvisé Pharmaceuticals is pleased to announce the successful completion of a transaction with AstraZeneca, regarding the acquisition of the commercial rights of Arimidex® (anastrozole) and Casodex® (bicalutamide) in a number of European, African and other countries.
This first transaction of Juvisé Pharmaceuticals with AstraZeneca is a logical next step after multiple worldwide deals accomplished by the French company with several other big pharmaceutical companies over the past years.
With this acquisition, Juvisé Pharmaceuticals enters the oncology therapeutic area, in which the company wants to further expand and consolidates its fast-growing ambition.
Frédéric Mascha, Founder and President of Juvisé Pharmaceuticals, declared “we are very pleased to have successfully closed our first deal with AstraZeneca and to enter a therapeutic area with high medical needs such as oncology with Arimidex® and Casodex®, which are two widely recognized cancer treatments essential for both patients and physicians”.
About Arimidex®
Arimidex® (anastrozole) is an aromatase inhibitor, indicated primarily for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer and the treatment of advanced breast cancer in postmenopausal women with disease progression, following tamoxifen therapy.
About Casodex®
Casodex® (bicalutamide) is an androgen-receptor inhibitor, indicated for use in combination therapy with a luteinising hormone-releasing hormone analogue for the treatment of Stage D2 metastatic carcinoma of the prostate.
About Juvisé Pharmaceuticals
Juvisé Pharmaceuticals is an international pharmaceutical company, specialized in manufacturing and commercializing ethical original drugs with high medical value for patients suffering from cardiovascular, oncology or neuro-psychiatric diseases.
11 years after its creation, Juvisé Pharmaceuticals has become a recognized international company commercializing its own drugs in 75 countries around the word.
For more information, please visit juvisepharmaceuticals.com.
Contacts
Media Relations
Soline LACOUR, Head of Sales & Marketing
Tel : +33 1 40 07 80 70 / Mail : soline.lacour@juvise.com
Investor Relations
Antoine GUILLOT, Chief Finance Officer
Tel : +33 4 26 29 40 15 / Mail : antoine.guillot@juvise.com
Press release published by LACOUR Soline
Published on 12/20/2019, 10:51 AM on 24presse.com
LACOUR Soline
Juvisé Pharmaceuticals
www.juvisepharmaceuticals.com
Contact
Press release free of rights. Mention : 24presse 24presse.com
Last press releases "sante"
Simbec-Orion acquires major part of the assets of Auxili...Published on 10/05/2021, 5:45 PM The Heart Fund Announces Successful Implementation of Se...Published on 09/29/2021, 12:21 PM Endometriosis : Innovation in the reduction of the main...Published on 03/05/2021, 7:00 PM France-Masques: The largest European platform dedicated ...Published on 07/22/2020, 11:55 AM KOMPAÏ : robot for healthcare facilities...Published on 05/14/2020, 2:37 PM COVID-19: free webinar brings together doctors and patie...Published on 05/14/2020, 9:30 AM COVID-19: A new reliable serological test...Published on 05/13/2020, 12:16 PM One innovative insurance broker is finding the perfect p...Published on 05/06/2020, 9:29 AM Institute LORIS AZZARO is involving in partnership with ...Published on 03/23/2020, 4:31 PM The French speciality pharmaceutical company, Juvisé Ph...Published on 12/20/2019, 10:51 AM